• JAYASHRI A. PATIL D.C.S’s A.R.A College of Pharmacy, Nagaon, Dhule
  • RAVINDRA B. PATIL D.C.S’s A.R.A College of Pharmacy, Nagaon, Dhule



Besifloxacin, non-erodible ocular insert, Pullulan, PVP, Eudragit RS-100


Objective: Ocular inserts offer many advantages over conventional dosage forms, like increased ocular residence, the possibility of releasing a drug at a slow and constant rate, accurate dosing, exclusion of preservatives, and increased shelf life. Besifloxacin is a very important drug for the treatment of infectious conjunctivitis. The present study was aimed to formulate and evaluate Besifloxacin Non-Erodible Ocular Insert using Pullulan and polyvinyl pyrrolidone as a drug reservoir, PEG 400 as a plasticizer, and Eudragit RS-100 as a rate-controlling membrane.

Methods: Central composite design was employed to study the effect of independent variables, i.e., effects of Pullulan amount (X1) and PVP (X2) on the dependent variables, i.e., % moisture absorption and In-vitro diffusion rate. After evaluation of all thirteen batches of ocular insert reservoir formulation BSF2 and BSF4 were selected as a satisfactory formulation and was sandwiched between rate-controlling membrane which was made up of Eudragit RS-100 (3 and 5%).

Results: The drug content of all formulations was found to be in the range of 95.33 to 99.89 %. In-vitro diffusion of Besifloxacin from reservoir formulations (BSF1 to BSF13) was found to be 62.44 to 70.62 %. In-vitro diffusion rate of an ocular insert of Besifloxacin can offer benefits such as increasing residence time, prolonging drug release in the eye for 24 h. Eudragit RS-100, as a sustained drug release polymer, showed promising sustained released action.

Conclusion: The study concluded that Besifloxacin non-erodible ocular inserts can be successfully developed using Pullulan and polyvinyl pyrrolidone which will sustain the release of the drug also reduce the frequency of administration, and thereby may help to improve patient compliance.


Download data is not yet available.


Hovding G. Acute bacterial conjunctivitis. Acta ophthalmologica. 2008 Feb;86(1):5-17.

Zhang JZ, Ward KW. Besifloxacin, a novel fluoroquinolone antimicrobial agent, exhibits potent inhibition of pro-inflammatory cytokines in human THP-1 monocytes. Journal of antimicrobial chemotherapy. 2008 Jan 1;61(1):111-16.

Tótoli EG, Salgado HR. Besifloxacin: a critical review of its characteristics, properties, and analytical methods. Critical reviews in analytical chemistry. 2018 Mar 4;48(2):132-42.

Chang MH, Fung HB. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis. Clinical therapeutics. 2010 Mar 1;32(3):454-71.

Majithiya RJ, Ghosh PK, Umrethia ML, Murthy RS. Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan. AAPS pharmscitech. 2006 Sep;7(3): 80-6.

Dawaba AM, Dawaba HM, El-enin AS, Khalifa MK. Fabrication of Bioadhesive Ocusert with Different Polymers: Once a Day Dose. International Journal of Applied Pharmaceutics. 2018 Nov 7:309-17.

Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. American journal of ophthalmology. 2001 Jan 1;131(1):131-33.

Gilhotra RM, Gilhotra N, Mishra DN. Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation. Current eye research. 2009 Dec 1;34(12):1065-3.

El-Gendy NA, Abdelbary GA, El-Komy MH, Saafan AE. Design and evaluation of a bioadhesive patch for topical delivery of gentamicin sulfate. Current drug delivery. 2009 Jan 1;6(1):50-7.

RAO MV, Shyale S. Preparation and evaluation of ocular inserts containing norfloxacin. Turkish Journal of Medical Sciences. 2004 Jul 27;34(4):239-46.

Harikumar SL, Balasubramaniam J, Kumar MT, Pandit JK. In vitro characterization of physically reinforced ocular inserts of Indomethacin. ACTA Pharmaceutica Sciencia. 2004;46(1).

Mundada AS, Shrikhande BK. Design and evaluation of soluble ocular drug insert for controlled release of ciprofloxacin hydrochloride. Drug development and industrial pharmacy. 2006 Jan 1;32(4):443-48.

Sreenivas SA, Hiremath SP, Godbole AM. Ofloxacin ocular inserts: Design, formulation and evaluation. Iranian journal of pharmacology & therapeutics. 2006 Dec 22;5(2):159-62.

Sankar V, Chandrasekaran AK, Durga S, Geetha G, Ravichandran V, Vijayakumar A, Raguraman S. Design and evaluation of diclofenac sodium ophthalmic inserts. Acta Pharmaceutica Sciencia. 2006;48(1).

El-Kamel A, Al-Dosari H, Al-Jenoobi F. Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride. Drug delivery. 2006 Jan 1;13(1):55-9.

Balasubramaniam J, Srinatha A, Nath G. In vitro microbiological evaluation of polyvinyl alcohol-based ocular inserts of ciprofloxacin hydrochloride. Indian journal of pharmaceutical sciences. 2006;68(5).

Jayaprakash S, Dachinamoorthi D, Ramkanth S, Nagarajan M, Sangeetha K. Formulation and evaluation of Gentamicin sulphate ocuserts. The Pharma Review. 2006:131-34.

Mukherjee P, Manvi FV, Sreenivas SA. Sulphacetamide sodium ocular inserts: Design, formulation and evaluation. INDIAN DRUGS-BOMBAY-. 2006;43(9):705.

Vijayendra Swamy SM, Nanjawade BK, Ravichandran M, Manvi FV. Development of sustained ocular drug delivery system for betaxolol. Indian Journal of Pharmaceutical Education and Research. 2006;40(3):165.

Gupta A, Sharma SK, Ahuja M. In vitro and in vivo evaluation of gellan based ocular inserts of phenylephrine. Acta Pharmaceutica Sciencia. 2007;49(1).

Eaga CM. In-situ gels- a novel approach for ocular drug delivery. Der. Pharmacia Lettre. 2009; 1:21-33.

Aburahma MH, Mahmoud AA. Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation. Aaps Pharmscitech. 2011 Dec; 12(4):1335-47.

Juliano C, Cossu M, Pigozzi P, Rassu G, Giunchedi P. Preparation, in vitro characterization and preliminary in vivo evaluation of buccal polymeric films containing chlorhexidine. AAPS Pharm Sci Tech. 2008; 9(4):1153–8.

Khan S, Ali A, Singhavi D, Pramod Y. Controlled ocular delivery of acyclovir trough rate controlling ocular insert of eudragit: A technical note. AAPS Pharm SciTech 2008; 9:169–172.

Niamprem PA, Srinivas SP, Tiyaboonchai WA. Development and characterization of indomethacin-loaded mucoadhesive nanostructured lipid carriers for topical ocular delivery. Int J Appl Pharm. 2018; 10(2):91-6.

Shankar V. A textbook of novel drug delivery system. Pharmamed press 2012;398-401.

Parmar RB, Tank HM. Design formulation and evaluation of reservoir type controlled released moxifloxacin hydrochloride ocular insert. Asian Journal of Research in Pharmaceutical Science. 2013;3(1):19-24.

Kalyanwat R, Shrivastava B, Pathak K. Preparation and Evaluation of Bioadhesive Ocular Inserts of Aceclofenac. Int. J. Pharm. Sci. Rev. Res., 2016; 41(2), Article No. 39, 207-213.

Jethava JK, Jethava GK. Design, formulation, and evaluation of novel sustain release bioadhesive in-situ gelling ocular inserts of ketorolac tromethamine. Int J Pharm Investig. 2014;4(4):226-32.

Zahraa H.F. Al-Saedi, Rami M. Alzhrani, and Sai H.S. Boddu.Journal of Ocular Pharmacology and Therapeutics. 2016.451-462.

Dhanaraju MD, Sivakumar VR, Subhashree R, Bhaskar K. Bioadhesive ocuserts matrix for ophthalmic administration of Ciprofloxacin hydrochloride. Indian drugs. 2002;39(4):222-4.

Khurana G, Arora S, Pawar PK. Ocular insert for sustained delivery of gatifloxacin sesquihydrate: Preparation and evaluations. Int J Pharm Investig. 2012 Apr;2(2):70-7.

Gilhotra RM, Nagpal K, Mishra DN. Azithromycin novel drug delivery system for the ocular application. Int J Pharm Investig. 2011;1(1):22-28.

Singh V, Bushetti SS, Raju SA, Ahmad R, Singh M, Ajmal M. Polymeric ocular hydrogels and ophthalmic inserts for controlled release of timolol maleate. J Pharm Bioallied Sci. 2011; 3(2):280-85.



How to Cite

PATIL, J. A., & B. PATIL, R. (2021). FORMULATION AND EVALUATION OF BESIFLOXACIN NON-ERODIBLE OCULAR INSERTS. International Journal of Applied Pharmaceutics, 14(1).



Original Article(s)